Information  X 
Enter a valid email address

MaxCyte, Inc. (MXCT)

  Print      Mail a friend

Monday 03 September, 2018

MaxCyte, Inc.

Notice of Half Year Results

RNS Number : 4933Z
MaxCyte, Inc.
03 September 2018
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Notice of Half Year Results

 

Gaithersburg, MD - 03 September 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, will announce its interim results for the six months ended 30 June 2018 on Monday 24 September 2018.

 

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11:00 BST on the day of the results at the offices of Panmure Gordon, 1 New Change, London EC4M 9AF.

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

 

 For more information, visit www.maxcyte.com.

 

###

 

 

 

 

 

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Ryan McCarthy

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

[email protected]

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORLTMMTMBIMTRP

a d v e r t i s e m e n t